How has been the historical performance of Gufic BioScience?

Answer:The historical performance of Gufic BioScience shows a mixed trend in its financial metrics for the fiscal year ending March 2025 compared to March 2024.

Breakdown:
In the fiscal year ending March 2025, Gufic BioScience reported net sales of 819.81 Cr, a slight increase from 806.67 Cr in March 2024. Total operating income also rose to 819.81 Cr from 806.67 Cr. However, the total expenditure, excluding depreciation, increased to 685.12 Cr from 660.79 Cr, driven by higher raw material costs and employee expenses. Consequently, the operating profit (PBDIT) decreased to 138.32 Cr from 148.06 Cr, leading to a decline in the operating profit margin from 18.08% to 16.43%. Profit before tax fell to 94.14 Cr from 115.67 Cr, and profit after tax decreased to 69.65 Cr from 86.14 Cr, resulting in a PAT margin decline from 10.68% to 8.5%. The earnings per share also dropped from 8.59 to 6.94. On the balance sheet, total liabilities remained stable at 1,092.54 Cr, while total assets were consistent with the previous year. The cash flow from operating activities was negative at -7.00 Cr, with a net cash outflow of 27.00 Cr, indicating challenges in cash generation despite the increase in sales.